RENBP and neoplasm: Notably, even low-dose NDV which infects only a minority of tumor cells (~20%, Supplementary Fig. 1a) enables anti-GFP T-cell killing of >99% of GFP+ A20 cells, indicating potentiation of Ag-specific killing even in non-infected cells.